Tax-driven sale of 1,660 uniQure (QURE) shares by CMO

Rhea-AI Filing Summary

uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an automatic sale of 1,660 ordinary shares in an open-market transaction at a weighted average price of $9.95 per share. The shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under pre-set instructions, and were not a discretionary trade. After this transaction, Abi-Saab直接 owns 148,777 ordinary shares. The sale price reflected multiple trades between $9.67 and $10.25.

Insights

Equity compensation analyst

Routine, tax-related insider sale tied to RSU vesting, not an elective share disposal.

The transaction involves 1,660 ordinary shares of uniQure N.V. sold by Chief Medical Officer Walid Abi-Saab at a weighted average price of $9.95. The filing states this was triggered by the vesting of restricted share units and pre-set sale instructions.

The shares were sold solely to cover estimated withholding taxes, meaning the transaction functions as a compensation-related tax event rather than an active portfolio decision. The filing also notes the price range from $9.67 to $10.25, with Abi-Saab retaining ownership of 148,777 shares afterward.

Insider Trade Summary

Net Seller: 1,660 shares ($16,517)

Net Sell 1 txn

Insider Abi-Saab Walid

Role Chief Medical Officer

Sold 1,660 shs ($17K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,660	$9.95	$17K

Holdings After Transaction: Ordinary Shares — 148,777 shares (Direct)

Footnotes (1)

1. The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.67 to $10.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abi-Saab Walid

(Last) (First) (Middle)

C/O UNIQURE N.V.

PAASHEUVELWEG 25A

(Street)

AMSTERDAM P7 11058BP

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/02/2026		S(1)		1,660(1)	D	$9.95(2)	148,777	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.67 to $10.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Christian Klemt, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did uniQure (QURE) report for Walid Abi-Saab?

uniQure (QURE) reported that Chief Medical Officer Walid Abi-Saab sold 1,660 ordinary shares. The sale was an open-market transaction linked to restricted share unit vesting and was executed under automatic instructions to cover estimated tax withholding obligations.

At what price were the 1,660 uniQure (QURE) shares sold by the CMO?

The 1,660 uniQure (QURE) ordinary shares were sold at a weighted average price of $9.95 per share. The filing explains trades occurred across multiple executions, with individual prices ranging from $9.67 to $10.25 during the transaction.

Was the uniQure (QURE) CMO’s sale of 1,660 shares discretionary?

No, the sale was not discretionary. The filing states the shares were automatically sold upon restricted share unit vesting under pre-set sale instructions, solely to cover estimated withholding taxes, rather than representing an elective decision by the chief medical officer to reduce holdings.

How many uniQure (QURE) shares does the CMO hold after this Form 4 transaction?

Following the reported sale, Chief Medical Officer Walid Abi-Saab directly owns 148,777 uniQure (QURE) ordinary shares. This post-transaction holding amount is explicitly reported in the filing as the total number of shares beneficially owned after the tax-related sale.

Why were uniQure (QURE) shares sold in connection with RSU vesting?

The filing explains that shares were sold upon the vesting of restricted share units to cover estimated withholding taxes. This is a common equity compensation mechanism where a portion of vested shares is sold automatically so the company can satisfy the insider’s tax obligations.